High prevalence of retinoblastoma protein loss in triple-negative breast cancers and its association with a good prognosis in patients treated with adjuvant chemotherapy

Annals of Oncology

Volumn 20, Issue 11, 2009, Pages 1818-1823

  Trere D ^a   Brighenti, E ^a   Donati, G ^a   Ceccarelli, C ^a   Santini, D ^b   Taffurelli, M ^a   Montanaro, L ^a   Derenzini, Massimo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Chemotherapy; P53; pRb; Prognosis; Triple negative breast cancer

Indexed keywords

CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; KI 67 ANTIGEN; METHOTREXATE; PROGESTERONE RECEPTOR; PROTEIN P53; RETINOBLASTOMA PROTEIN; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; METHOTREXATE; MIDDLE AGED; NEOPLASM STAGING; PREVALENCE; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETINOBLASTOMA PROTEIN; TUMOR MARKERS, BIOLOGICAL;

EID: 70350460641     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp209     Document Type: Article

References (36)

1. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
2. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874.
3. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 8418-8423.
4. Reis-Filho JS, Westbury C, Pierga JY. The impact of expression profiling on prognostic and predictive testing in breast cancer. J Clin Pathol 2006; 59: 225-231.
5. Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: Ready for clinical application? J Clin Oncol 2005; 23: 7350-7360.
6. Rouzier R, Perou CM, Symmans WF et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 11: 5678-5685.
7. Reis-Filho JS, Tutt AN. Triple negative tumours: A critical review. Histopathology 2008; 52: 108-118.
8. Derenzini M, Donati G, Mazzini G et al. Loss of retinoblastoma tumor suppressor protein makes human breast cancer cells more sensitive to antimetabolite exposure. Clin Cancer Res 2008; 14: 2199-2209.
9. Faccioli S, Chieco P, Gramantieri L et al. Cytometric measurement of cell proliferation in echo-guided biopsies from focal lesions of the liver. Mod Pathol 1996; 9: 120-125.
10. Ellis IO, Bartlett J, Dowsett M et al. Best Practice No 176. Updated recommendations for HER2 testing in the UK. J Clin Pathol 2004; 57: 233-237.
11. Nielsen TO, Hsu FD, Jensen K et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10: 5367-5374.
12. Carey LA, Perou CM, Livasy CA et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295: 2492-2502.
13. Carey LA, Dees EC, Sawyer L et al. The triple negative paradox. primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007; 13: 2329-2334.
14. Dent R, Trudeau M, Pritchard KI et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429-4434.
15. Derenzini M, Ceccarelli C, Santini D et al. The prognostic value of the AgNOR parameter in human breast cancer depends on the pRb and p53 status. J Clin Pathol 2004; 57: 755-761.
16. Hayes DF. Markers of increased risk for failure of adjuvant therapies. Breast 2003; 12: 543-549.
17. Goldhirsch A, Wood WC, Gelber RD et al. Meeting Highlights. Updated International Expert Consensus on the Primary Therapy of Early Breast Cancer. J Clin Oncol 2003; 21: 3357-3365.
18. Liedtke C, Mazouni C, Hess KR et al. Response to neoadjuvant therapy and longterm survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26: 1275-1281.
19. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995; 81: 323-330.
20. Sherr CJ. The Pezcoller lecture: Cancer cell cycle revisited. Cancer Res 2000; 60: 3689-3695.
21. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10: 789-799.
22. Harbour JW, Luo RX, Dei Santi A et al. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 1999; 98: 859-869.
23. Zhang HS, Gavin M, Dahiya A et al. Exit from G1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF. Cell 2000; 101: 79-89.
24. Sherr CJ. Cancer cell cycles. Science 1996; 274: 1672-1677.
25. David-Pfeuty T. The flexible evolutionary anchorage-dependent Pardee's restriction point of mammalian cells. How its deregulation may lead to cancer. Biochim Biophys Acta 2006; 1765: 38-66.
26. Sherr CJ, Roberts JM. CDK inhibitors: Positive and negative regulators of G1- phase progression. Genes Dev 1999; 13: 1501-1512.
27. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002; 2: 103-112.
28. Cordon-Cardo C. Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol 1995; 147: 545-560.
29. Knudsen ES, Knudsen KE. Tailoring to RB: Tumour suppressor status and therapeutic response. Nat Rev Cancer 2008; 9: 714-724.
30. Knudsen KE, Booth D, Naderi S et al. RB-dependent S-phase response to DNA damage. Mol Cell Biol 2000; 20: 7751-7763.
31. Angus SP, Wheeler LJ, Ranmal SA et al. Retinoblastoma tumor suppressor targets dNTP metabolism to regulate DNA replication. J Biol Chem 2000; 277: 44376-44384.
32. Bosco EE, Mayhew CN, Hennigan RF et al. RB signaling prevents replication-dependent DNA double-strand breaks following genotoxic insult. Nucleic Acids Res 2004; 32: 25-34.
33. Wang W, Cassidy J, O'Brien V et al. Mechanistic and predictive profiling of 5- fluorouracil resistance in human cancer cells. Cancer Res 2004; 64: 8167-8176.
34. Herschkowitz JI, He X, Fan C, Perou CM. The functional loss of the retinoblastoma tumor suppressor is a common event in basal-like and luminal B breast carcinomas. Breast Cancer Res 2008; 10: R75.
35. Korsching E, Jeffrey SS, Meinerz W et al. Basal carcinoma of the breast revisited: An old entity with new interpretations. J Clin Pathol 2008; 61: 553-560.
36. Diaz LK, Cryns VL, Symmans WF, Sneige N. Triple negative breast carcinoma and the basal phenotype: From expression profiling to clinical practice. Adv Anat Pathol 2007; 14: 419-430.